 Epoprostenol
"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 2 | 2 | | 1994 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 3 | 2 | 5 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 2 | 5 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 5 | 9 | | 2010 | 2 | 3 | 5 | | 2011 | 0 | 1 | 1 | | 2012 | 4 | 1 | 5 | | 2013 | 3 | 2 | 5 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2020 | 2 | 0 | 2 | | 2021 | 0 | 3 | 3 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Douwes JM, Zijlstra WMH, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG, Roofthooft MTR, Postmus D, Hillege HL, Ivy DD, Berger RMF. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Ann Am Thorac Soc. 2022 02; 19(2):227-237.
-
Tennis MA, Smith AJ, Dwyer-Nield LD, Keith RL. Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model. Cancer Prev Res (Phila). 2022 01; 15(1):11-16.
-
Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2021 03; 56(3):661-669.
-
Coleman RD, Chartan CA, Mourani PM. Intensive care management of right ventricular failure and pulmonary hypertension crises. Pediatr Pulmonol. 2021 03; 56(3):636-648.
-
Hopper RK, Ivy DD, Yung D, Mullen MP, Hanna BD, Kirkpatrick E, Hirsch R, Austin ED, Fineman J, Solum D, Deng CQ, Feinstein JA. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2020 07; 76(1):94-100.
-
Wang L, Halliday G, Huot JR, Satoh T, Baust JJ, Fisher A, Cook T, Hu J, Avolio T, Goncharov DA, Bai Y, Vanderpool RR, Considine RV, Bonetto A, Tan J, Bachman TN, Sebastiani A, McTiernan CF, Mora AL, Machado RF, Goncharova EA, Gladwin MT, Lai YC. Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Arterioscler Thromb Vasc Biol. 2020 06; 40(6):1543-1558.
-
Hall K, Ogawa M, Sakarovitch C, Hopper RK, Adamson GT, Hanna B, Ivy DD, Miller-Reed K, Yung D, McCarthy E, Siehr-Handler SL, Feinstein JA. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. J Cardiovasc Pharmacol. 2019 06; 73(6):383-393.
-
Barnes H, Yeoh HL, Fothergill T, Burns A, Humbert M, Williams T. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2019 May 01; 5:CD012785.
-
New ML, White CM, McGonigle P, McArthur DG, Dwyer-Nield LD, Merrick DT, Keith RL, Tennis MA. Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila). 2018 10; 11(10):643-654.
-
Tamosiuniene R, Manouvakhova O, Mesange P, Saito T, Qian J, Sanyal M, Lin YC, Nguyen LP, Luria A, Tu AB, Sante JM, Rabinovitch M, Fitzgerald DJ, Graham BB, Habtezion A, Voelkel NF, Aurelian L, Nicolls MR. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circ Res. 2018 06 08; 122(12):1689-1702.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|